EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Targeting of demyelinated lesions in experimental models of multiple sclerosis using a fibrin binding peptide

Sahar Farhangi, vahid sheibani, Mohammad Javan

Physiology and Pharmacology · 01.12.2025 · 29 (4) · 484-491

DOI: 10.66224/phypha.29.4.484 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Physiology and Pharmacology, online erschienen am 01.12.2025. Verfasst von Sahar Farhangi und 2 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Multiple sclerosis (MS) is an autoimmune and inflammatory disease of the central nervous system characterized by demyelination, astrogliosis, blood-brain barrier (BBB) disruption, and axonal damage.Currently available clinical and experimental approaches for MS are not completely effective because of the inability to pass the BBB, off-target distribution, and the need to increase the dosage.It has been shown that BBB disruption and fibrin deposition occur in the region of lesions in MS.Coagulation factor XIII binds to fibrin through the heptapeptide NQEQVSP in its structure.Here, NQEQVSP was used to target the lesions in animal models of MS.

Methods

Microglia, astrocytes, and oligodendrocytes were immuno-stained using antibodies against Iba1, GFAP, and MBP, respectively.

Results

We showed that peptide NQEQVSP binding was specific to the lesion sites induced by lysophosphatidylcholine (LPC) injection into the corpora callosa of mice.The peptide was FAM labeled, and its co-localization with different glial cells was evaluated.Co-localization was mainly detected with the microglia in the damaged area.A lower level of co-localization was also observed for oligodendrocytes.

Conclusion

Our results promise the possibility of using NQEQVSP peptide to target the lesions for specific drug delivery in patients suffering from multiple sclerosis. www.phypha.ir/ppjExperimental Research Article Physiology and Pharmacology 29 (2025) 484-491Multiple sclerosis (MS) is a chronic autoimmune and inflammatory demyelinating disease of the central ner-vous system (CNS).MS usually occurs in young adults between 20-40 years of age, with a higher prevalence in females (Ford 2020).There is no cure for MS.However,

Zitieren

APA

Farhangi, S., sheibani, V., & Javan, M. (2025). Targeting of demyelinated lesions in experimental models of multiple sclerosis using a fibrin binding peptide. Physiology and Pharmacology, 29(4), 484-491. https://doi.org/10.66224/phypha.29.4.484

Vancouver

Farhangi S, sheibani V, Javan M. Targeting of demyelinated lesions in experimental models of multiple sclerosis using a fibrin binding peptide. Physiology and Pharmacology. 2025;29(4):484-491. doi:10.66224/phypha.29.4.484

BibTeX
@article{Farhangi2025,
  author = {Farhangi, Sahar and sheibani, vahid and Javan, Mohammad},
  title = {Targeting of demyelinated lesions in experimental models of multiple sclerosis using a fibrin binding peptide},
  journal = {Physiology and Pharmacology},
  year = {2025},
  volume = {29},
  number = {4},
  pages = {484--491},
  doi = {10.66224/phypha.29.4.484}
}
Kostenlos starten →